{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:39:44Z","timestamp":1773916784410,"version":"3.50.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Double seronegative myasthenia gravis (dSnMG) is defined as myasthenia gravis (MG) without detectable antibodies to acetylcholine receptor (AChR) and muscle-specific kinase (MuSK). Absence of a disease-specific biomarker and clinical heterogeneity can significantly complicate diagnostic pathway. This study aimed to identify cases misdiagnosed as dSnMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>The study included 33 patients [64% females, median age at onset 30 (22.5\u201340) years, median age at testing 46 (34\u201358) years] previously diagnosed with dSnMG. Disease severity was assessed using MG-ADL and QMG at testing, peak MGFA, intensive care unit (ICU) hospitalization and MG crisis history. Indirect immunofluorescence was performed to detect low-density lipoprotein receptor-related protein 4 (LRP4) antibodies. Whole exome sequencing (WES) was conducted, along with genetic testing for myotonic dystrophy type 1 and 2 (DM1 and DM2) and oculopharyngeal muscular dystrophy (OPMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean MG-ADL and QMG scores at testing were 1 (0\u20133) and 6 (3\u20139), respectively. More than half of the patients had ocular MG (52%). One patient experienced myasthenic crisis. One patient tested positive for LRP4 antibodies, and one was diagnosed with paraneoplastic Lambert\u2013Eaton myasthenic syndrome. WES showed likely pathogenic variant c.517G &amp;gt; A in the\n                      <jats:italic>CHRNA1<\/jats:italic>\n                      gene associated with autosomal dominant slow channel congenital myasthenic syndrome and only one variant c.2368G &amp;gt; A in the\n                      <jats:italic>MUSK<\/jats:italic>\n                      gene. One patient displayed a DM2 premutation (32\u201335 CCTG repeats).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights the importance of considering alternative diagnoses in patients with dSnMG and emphasizes the value of comprehensive testing. Early recognition of causative etiologies can significantly improve patient management and outcome and prevent unnecessary exposure to prolonged immunosuppression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1754393","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:23:16Z","timestamp":1773897796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hidden diagnoses among patients with double seronegative myasthenia gravis"],"prefix":"10.3389","volume":"17","author":[{"given":"Vukan","family":"Ivanovic","sequence":"first","affiliation":[{"name":"Neurology Clinic, University Clinical Center of Serbia","place":["Belgrade, Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stojan","family":"Peric","sequence":"additional","affiliation":[{"name":"Neurology Clinic, University Clinical Center of Serbia","place":["Belgrade, Serbia"]},{"name":"Faculty of Medicine, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Briggs","sequence":"additional","affiliation":[{"name":"Dianthus Therapeutics","place":["New York, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Marjanovic","sequence":"additional","affiliation":[{"name":"Neurology Clinic, University Clinical Center of Serbia","place":["Belgrade, Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovan","family":"Pesovic","sequence":"additional","affiliation":[{"name":"Faculty of Biology, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Basta","sequence":"additional","affiliation":[{"name":"Neurology Clinic, University Clinical Center of Serbia","place":["Belgrade, Serbia"]},{"name":"Faculty of Medicine, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Jansson","sequence":"additional","affiliation":[{"name":"Dianthus Therapeutics","place":["New York, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simrat","family":"Randhawa","sequence":"additional","affiliation":[{"name":"Dianthus Therapeutics","place":["New York, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Rajic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sankalp","family":"Gokhale","sequence":"additional","affiliation":[{"name":"Dianthus Therapeutics","place":["New York, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.3390\/brainsci13091286","article-title":"Diagnosis and management of seronegative myasthenia gravis: lights and shadows","volume":"13","author":"Vinciguerra","year":"2023","journal-title":"Brain Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"101665","DOI":"10.1016\/j.lanwpc.2025.101665","article-title":"SCREAM study investigators. a multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study","volume":"63","author":"Li","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"B6","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"8","author":"Jacob","year":"2012","journal-title":"Arch Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","article-title":"Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis","volume":"93","author":"Damato","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13023-023-02727-0","article-title":"Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey","volume":"18","author":"Mahic","year":"2023","journal-title":"Orphanet J Rare Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/mus.21185","article-title":"Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve."},{"key":"B13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/cge.13848","article-title":"Diagnostic yield and clinical utility of whole exome sequencing using an automated variant prioritization system, evidence","volume":"98","author":"Seo","year":"2020","journal-title":"Clin Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"D1207","DOI":"10.1093\/nar\/gkaa1043","article-title":"The human phenotype ontology in 2021","volume":"49","author":"K\u00f6hler","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ajhg.2009.09.003","article-title":"Clinical diagnostics in human genetics with semantic similarity searches in ontologies","volume":"85","author":"K\u00f6hler","year":"2009","journal-title":"Am J Hum Genet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"391821","DOI":"10.1155\/2013\/391821","article-title":"Molecular genetics and genetic testing in myotonic dystrophy type 1","volume":"2013","author":"Savi\u0107 Pavi\u0107evi\u0107","year":"2013","journal-title":"Biomed Res Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1038\/s41467-022-30015-1","article-title":"Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1590\/0004-282x-anp-2020-0575","article-title":"Congenital myasthenic syndrome in a cohort of patients with \u2018double' seronegative myasthenia gravis","volume":"80","author":"Lorenzoni","year":"2022","journal-title":"Arq Neuropsiquiatr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mus.21919","article-title":"Investigation for RAPSN and DOK-7 mutations in a cohort of seronegative myasthenia gravis patients","volume":"43","author":"Alseth","year":"2011","journal-title":"Muscle Nerve."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1770","DOI":"10.1212\/WNL.0000000000006478","article-title":"Congenital myasthenic syndromes in adult neurology clinic: a long road to diagnosis and therapy","volume":"91","author":"Kao","year":"2018","journal-title":"Neurology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/ene.13300","article-title":"Multiple antibody detection in \u2018seronegative' myasthenia gravis patients","volume":"24","author":"Hong","year":"2017","journal-title":"Eur J Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/ene.13081","article-title":"Electrophysiological findings in patients with low density lipoprotein receptor related protein 4 positive myasthenia gravis","volume":"23","author":"Nikolic","year":"2016","journal-title":"Eur J Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/1744666X.2021.1936500","article-title":"Heterogeneity in myasthenia gravis: considerations for disease management","volume":"17","author":"Evoli","year":"2021","journal-title":"Expert Rev Clin Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody-positive myasthenia gravis: a multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve."},{"key":"B28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/B978-0-12-823912-4.00012-8","article-title":"Lambert\u2013Eaton myasthenic syndrome","volume":"200","author":"Lipka","year":"2024","journal-title":"Handb Clin Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert\u2013Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clin Pharmacol Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1007\/s00415-022-11458-4","article-title":"Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis","volume":"270","author":"Kwon","year":"2023","journal-title":"J Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1017\/cjn.2016.268","article-title":"Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports","volume":"43","author":"Merino-Ram\u00edrez","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.nmd.2017.08.003","article-title":"Molecular characterization of congenital myasthenic syndromes in Spain","volume":"27","author":"Natera-de Benito","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"B34","doi-asserted-by":"publisher","first-page":"P6","DOI":"10.1016\/j.jneuroim.2008.06.026","article-title":"Congenital myasthenic syndromes in childhood: diagnostic and management challenges","volume":"201","author":"Kinali","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/mus.25085","article-title":"Late presentations of congenital myasthenic syndromes\u2014how many do we miss?","volume":"54","author":"Garg","year":"2016","journal-title":"Muscle Nerve."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e214177","DOI":"10.1212\/WNL.0000000000214177","article-title":"Screening for congenital myasthenic syndromes in adults with seronegative myasthenia gravis using next-generation sequencing","volume":"105","author":"Krenn","year":"2025","journal-title":"Neurology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1093\/hmg\/ddh333","article-title":"MUSK, a new target for mutations causing congenital myasthenic syndrome","volume":"13","author":"Chevessier","year":"2004","journal-title":"Hum Mol Genet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.xhgg.2024.100288","article-title":"The severity of MUSK pathogenic variants is predicted by the protein domain they disrupt","volume":"5","author":"Cocanougher","year":"2024","journal-title":"HGG Adv."},{"key":"B39","doi-asserted-by":"publisher","first-page":"932883","DOI":"10.3389\/fneur.2022.932883","article-title":"Autoimmune diseases in patients with myotonic dystrophy type 2","volume":"13","author":"Peric","year":"2022","journal-title":"Front Neurol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-0028-1090103","article-title":"Coincidence of myasthenia gravis and myotonic dystrophy type 2","volume":"39","author":"Bamberg","year":"2008","journal-title":"Klin Neurophysiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3988\/jcn.2013.9.2.130","article-title":"The coexistence of myasthenia gravis and myotonic dystrophy type 2 in a single patient","volume":"9","author":"Nikolic","year":"2013","journal-title":"J Clin Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10072-022-06507-9","article-title":"Clinical score for early diagnosis of myotonic dystrophy type 2","volume":"44","author":"Ivanovic","year":"2023","journal-title":"Neurol Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"668094","DOI":"10.3389\/fgene.2021.668094","article-title":"A 14-Year Italian experience in DM2 genetic testing: frequency and distribution of normal and premutated CNBP alleles","volume":"12","author":"Botta","year":"2021","journal-title":"Front Genet."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1754393\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:23:17Z","timestamp":1773897797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1754393\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":43,"alternative-id":["10.3389\/fneur.2026.1754393"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1754393","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"article-number":"1754393"}}